Scientists are increasingly discovering new ways that our microbiome - the community of bacteria and viruses that live inside ...
The incidence of a composite cardiovascular disease (CVD) end point is increased among older adults with cancer, especially ...
New anecdotal evidence suggests some chemoimmunotherapy treatments may improve pulmonary arterial hypertension symptoms, but the overall evidence remains murky.
Over the last century, the U.S. armed forces resorted to asbestos-containing products as WWII demanded accessible materials ...
About 40% of Americans will develop a form of cancer at some point in their lifetime, according to the American Cancer ...
Lung cancer is the leading cause of cancer-related deaths, and the most common form is a non-small-cell type called adenocarcinoma.
AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically ...
Lung cancer is one of the most common and aggressive cancers. Its most characteristic symptoms include coughing, shortness of ...
AstraZeneca's cancer drug, datopotamab deruxtecan, failed to meet targets in a Phase 3 trial, clouding the possibility of approval from the U.S. Food and Drug Administration. Shares were down 1.2% at ...
Amivantamab plus chemo is now indicated in locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R ...
New research highlights increased stroke, heart attack, and heart failure risks in cancer survivors, especially those treated ...